Cerus Corporation (CERS): Price and Financial Metrics

Cerus Corporation (CERS): $6.20

0.30 (+5.08%)

POWR Rating

Component Grades













Add CERS to Watchlist
Sign Up

Industry: Biotech


of 488

in industry

CERS Stock Summary

  • With a price/sales ratio of 8.69, Cerus Corp has a higher such ratio than 80.7% of stocks in our set.
  • As for revenue growth, note that CERS's revenue has grown 21.83% over the past 12 months; that beats the revenue growth of 79.61% of US companies in our set.
  • In terms of volatility of its share price, CERS is more volatile than merely 16.83% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cerus Corp are GTHX, PSNL, KIN, EH, and EPZM.
  • CERS's SEC filings can be seen here. And to visit Cerus Corp's official web site, go to www.cerus.com.

CERS Stock Price Chart Interactive Chart >

Price chart for CERS

CERS Price/Volume Stats

Current price $6.20 52-week high $8.87
Prev. close $5.90 52-week low $2.71
Day low $5.51 Volume 6,863,500
Day high $6.26 Avg. volume 2,164,032
50-day MA $7.18 Dividend yield N/A
200-day MA $6.65 Market Cap 1.04B

Cerus Corporation (CERS) Company Bio

Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.

CERS Latest News Stream

Event/Time News Detail
Loading, please wait...

CERS Latest Social Stream

Loading social stream, please wait...

View Full CERS Social Stream

Latest CERS News From Around the Web

Below are the latest news stories about Cerus Corp that investors may wish to consider to help them evaluate CERS as an investment opportunity.

Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit

Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Thursday, March 11, 2021 at 11:00 am PT/ 2:00 pm ET.

Yahoo | March 3, 2021

Cerus Corporation's (CERS) CEO Obi Greenman on Q4 2020 Results - Earnings Call Transcript

Cerus Corporation (CERS) Q4 2020 Results Earnings Conference Call February 25, 2021, 4:30 PM ET Company Participants Matt Notarianni - Senior Director, Investor Relations Obi Greenman - President and CEO Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President, Regulatory Affairs...

SA Transcripts on Seeking Alpha | February 26, 2021

Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China

Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System for platelets and red blood cells in China. The JV, which will be named "Cerus ZBK Biomedical" (CEZB), will be headquartered in Zibo, Shandong Province in eastern China.

Yahoo | February 24, 2021

A Preview Of Cerus's Earnings

On Thursday, February 25, Cerus (NASDAQ:CERS) will release its latest earnings report. Benzinga's outlook for Cerus is included in the following report. What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Cerus's per-share loss will be near $0.09 on sales of $32.42 million, according to Wall Street analysts. In the same quarter last year, Cerus posted EPS of $0.12 on sales of $20.92 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Analysts who cover this company wi...

Yahoo | February 24, 2021

Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides,

Business Wire | February 11, 2021

Read More 'CERS' Stories Here

CERS Price Returns

1-mo -17.77%
3-mo -15.53%
6-mo 7.36%
1-year 12.93%
3-year 29.17%
5-year 16.54%
YTD -10.40%
2020 63.98%
2019 -16.77%
2018 50.00%
2017 -22.30%
2016 -31.17%

Continue Researching CERS

Want to see what other sources are saying about Cerus Corp's financials and stock price? Try the links below:

Cerus Corp (CERS) Stock Price | Nasdaq
Cerus Corp (CERS) Stock Quote, History and News - Yahoo Finance
Cerus Corp (CERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9598 seconds.